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Background. There are conflicting data on the prevalence of coronary events and the quality of the management of modifiable
cardiovascular risk factors (CVRF) inHIV-infected patients.Methods.We performed a retrospective descriptive study to determine
the prevalence of coronary events and to evaluate the management of CVRF in a Mediterranean cohort of 3760 HIV-1-infected
patients from April 1983 through June 2011. Results. We identified 81 patients with a history of a coronary event (prevalence 2.15%);
83% of them suffered an acute myocardial infarction. At the time of the coronary event, CVRF were highly prevalent (60.5%
hypertension, 48%dyslipidemia, and 16%diabetesmellitus). OtherCVRF, such as smoking, hypertension, lack of exercise, and body
mass index, were not routinely assessed. After the coronary event, a significant decrease in total cholesterol (𝑃 = 0.025) and LDL-
cholesterol (𝑃 = 0.004)was observed. However, the percentage of patients whomaintained LDL-cholesterol > 100mg/dL remained
stable (from 46% to 41%, 𝑃 = 0.103). Patients using protease inhibitors associated with a favorable lipid profile increased over time
(𝑃 = 0.028).Conclusions.The prevalence of coronary events in our cohort is low. CVRF prevalence is high and their management is
far from optimal. More aggressive interventions should be implemented to diminish cardiovascular risk in HIV-infected patients.
1. Introduction
The increased life expectancy of the HIV-1-infected popu-
lation means that physicians are increasingly being faced
with previously unrecognized comorbid conditions and
antiretroviral-related complications. Atherosclerosis and car-
diovascular events, loss of renal function, osteopenia/
osteoporosis, and non-AIDS-defining cancers are some of the
emerging conditions observed in large observational cohorts,
and their incidence seems to be higher than in the general
population [1–7]. In addition, not only is HIV infection
associated with AIDS-defining neurologic conditions with
severe CD4 depletion, but also HIV-associated neurocogni-
tive disorders seem more common in HIV-infected individ-
uals despite achieving a successful immune recovery.
Several studies, including the data collection on adverse
events of anti-HIV drugs (D.A.D.) study, have demon-
strated an increased rate of premature cardiovascular events,
including myocardial infarction, in HIV-1-infected individ-
uals exposed to specific individual antiretroviral drugs [8–
14]. Traditional cardiovascular risk factors (CVRF) have
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at least a similar impact on cardiovascular disease (CVD)
in this population as they do in the general population
[15–17]. However, both HIV replication and antiretroviral
therapy may contribute independently to an increased risk
of CVD [4, 8–14, 18–20]. Several hypotheses have been
formulated to explain a potential increase in the incidence
of premature aging and coronary events in these patients
[3, 4, 18–23]. Some mechanisms are related to antiretroviral
therapy, such as the mitochondrial dysfunction and oxidative
stress induced by thymidine analogues [10–12] or protease
inhibitor- (PI-) related dyslipemia [8, 9, 13, 14], while the
virus itself contributes to increased cardiovascular risk by a
chronic inflammatory effect or a direct effect on endothelial
and other cells [4, 20, 21]. These factors, together with the
increased incidence of traditional CVRF in HIV-1-infected
patients, could pave the way to the development of coronary
events [4, 8–14, 16, 19–24].
Encouraging data suggest that the incidence of ischemic
heart disease in HIV-1-infected patients could be decreasing
in recent years, probably due to the use of new antiretroviral
regimens associated with higher suppression rates of HIV-1
replication and more favorable lipid profiles [25]. However,
data on the excellence in the control of modifiable CVRF in
HIV-infected individuals are scant.
We assessed the management of CVRF in the routine
clinical practice in HIV-infected subjects already diagnosed
for a coronary event.
2. Methods
2.1. Study Design and Population. We performed a retrospec-
tive descriptive study to identify all HIV-1-infected patients
with a previous coronary event recorded in the database of
the HIV unit, internal medicine and cardiology departments
of two tertiary hospitals in Barcelona, Spain, from April
1983 through June 2011. The database contained information
on 3,760 HIV-1-infected patients in routine follow-up. In
addition, the causes of mortality in both cohorts during the
period of study (from April 1983 to June 2011) have been
checked to identify those related to a cardiovascular event.
A coronary event was defined as a definite or probable
acute myocardial infarction or reinfarction, angina, per-
cutaneous coronary angioplasty/stenting, coronary bypass
surgery, target vessel revascularization for restenosis, stent
thrombosis, and death from ischemic coronary disease
according to the criteria of the World Health Organization
Multinational Monitoring of Trends and Determinants in
Cardiovascular Disease Project (MONICA) [26].
Cases of myocardial infarction were categorized as fatal
or nonfatal.
2.2. Study Objectives and Endpoints. We determined the
prevalence of coronary events by assessing the numbers of
subjects per 1000 HIV-infected patients in a Mediterranean
cohort to identify all HIV-1-infected patients with a previous
coronary event recorded in the database fromApril 1983 until
June 2011.
To evaluate changes in modifiable CVRF before and
after the coronary event, we compared the prevalence of the
modifiable CVRF in the clinic at three time points: before
initiating antiretroviral therapy, at the time of the coronary
event, and after the event (the last available visit until June
2011).
Finally, we compared the Framingham risk score at the
time of the coronary event and at last follow-up visit.
2.3. Assessments. We recorded the following information:
sociodemographic features (age, gender, and race); HIV-
related data (time since HIV diagnosis, risk behavior, pre-
vious AIDS diagnosis defined according to the Centers for
Disease Control and Prevention category C [27], time on
antiretroviral therapy, time on HAART, nadir CD4 T-cell
count, and cumulative exposure to antiretroviral drugs such
as nonnucleoside reverse transcriptase inhibitors [NNRTI],
the nucleoside reverse transcriptase inhibitor [NRTI] aba-
cavir, and protease inhibitors (PIs)); personal and family
history of hypertension, diabetes mellitus, dyslipidemia, pre-
vious cardiovascular events, nephropathy, hepatitis coinfec-
tion, use of concomitant therapy (treatment for dyslipidemia,
hypertension, and diabetes mellitus); body mass index; the
practice of regular exercise (at least 3 hours per week
of cardiovascular exercise); consumption of drugs, coffee,
alcohol, and tobacco.
In addition, at each of the three time points mentioned
above, we recorded laboratory data performed after at least 8
hours of fasting (plasma HIV-1 RNA levels, lymphocyte CD4
T-cell count, total cholesterol, low-density lipoprotein [LDL]
cholesterol, high-density lipoprotein [HDL] cholesterol,
triglycerides, glomerular filtration rate, and glucose level) and
the Framingham risk score.Glycosylated hemoglobinwas not
considered because it was not a routine laboratory parameter.
Cardiovascular risk was classified according to the Fram-
ingham score as low (<10%), moderate (10%–20%), or high
(≥20%).
Hypertension was defined as systolic blood pressure
≥140mmHg, diastolic blood pressure ≥90mmHg, or the
need for antihypertensive drugs. Patients were considered to
have dyslipidemia if they were taking lipid-lowering drugs
or when the total cholesterol level was >200mg/dL, LDL-
cholesterol level was >100mg/dL (criteria for HIV-infected
patients according to the “European Guidelines on cardio-
vascular disease prevention in clinical practice” [28]), and/or
triglycerides were >200mg/dL.
Antiretroviral drugs were classified according to their
impact on lipid metabolism in two groups: those with a neg-
ative impact on triglyceride and cholesterol levels (lopinavir,
indinavir, and fosamprenavir) and those with a neutral effect
(atazanavir, saquinavir, darunavir, and NNRTIs).
2.4. Statistical Analysis. Demographic and clinical param-
eters were expressed as mean (SD), median (interquartile
range, IQR), or frequency and percentage, as appropriate.
Continuous repeated measurements were compared
using the 𝑡-test, Wilcoxon test, or Friedman test; proportions
were compared using the McNemar test or Cochran test.
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Univariate 𝑃 values <0.05 were considered significant.
All statistical analyses were performed using SPSS software,
version 15.0.0 (SPSS Inc, Chicago, Illinois, USA).
3. Results
We identified 81 HIV-1-infected patients with a previous
coronary event in a cohort of 3760 patients. The prevalence
of a coronary event was 2.15%.
3.1. Coronary Event. The most frequent event was acute
myocardial infarction (67 patients, 82.7%), followed by unsta-
ble angina (10 patients, 12%), reinfarction, or angor following
acute myocardial infarction (4 patients, 5.3%).
Coronary angiography was undertaken in 43 patients
(53%) and revealed stenosis with single vessel involvement in
19 of them (41.9%) and 2 or more vessels in 25 (58.1%).
Forty-six patients (57%) received invasive treatment: 24
of them (30%) received a percutaneous angioplasty, 18 (22%)
open bypass surgery, and 4 (5%) vessel revascularization for
restenosis and stent thrombosis. The remaining 35 patients
(43%) only required medical treatment.
The mortality rate registered in our cohort among sub-
jects with previous coronary events at the end of study (June
2011) was 13.6% (11/81). Of these, 9 (11%) patients died due
to noncardiovascular causes such as kidney failure, liver
failure, opportunistic infections, brain subdural hematomas,
respiratory infections, and others, and only two patients
(2.5%) died as a result of a coronary event (one of them was
related to illicit drug use, cocaine).
3.2. Patient Data at the Time of the Coronary Event. Table 1
shows the traditional CVRF and the epidemiologic and HIV-
related characteristics of the patients at the time of the
coronary event.
From 81HIV-1-infected patients with a previous coronary
event, overall 86% of themweremales, themedian age was 48
(40, 57) years, and 38% of patients were >50 years old.
As for CVRF, 60.5% of patients had a history of hyper-
tension, 48% dyslipidaemia, and 16% diabetes mellitus; of
them, 12.2%, 23.1%, and 11.4% required treatment for these
conditions, respectively, but they did not receive it or this
information was not available in the patient’s records. Forty-
four percent of patients were current smokers and 9.8% had a
bodymass index>25.The information in themedical records
revealed that only 3 patients (3.7%) were questioned about
physical exercise.
At the time of the coronary event, the median follow-
up since diagnosis of HIV infection was 14.9 (10.4; 19.2)
years, the median time (IQR) from starting antiretroviral
treatment until the coronary event and themedian time from
the coronary event until the last follow-up visit (June 2011)
were 8 (5; 12) and 7 (4; 11) years, respectively, and the median
time of receiving antiretroviral treatment was 12.7 (9.3,
16.2) years. Regarding antiretroviral treatment, 33 patients
(41%) were receiving a PI-based regimen: 22 patients (67%)
were receiving PI-based regimen with an unfavorable lipid
profile and 11 (33%) a PI-based regimen with favorable lipid
profile; 26 (32%) were receiving a NNRTI-based regimen: 11
patients were on efavirenz (42%) and 15 on nevirapine (58%);
6 patients (7%) were receiving other regimens (integrase
inhibitors, CCR5 antagonist) and 17 patients (20%) were not
taking antiretroviral treatment.
At the time of the coronary event, the calculation of
Framingham score was only possible in 12 patients (15%)
due to the lack of some necessary parameters (mainly
determination of HDL-cholesterol levels, tobacco, and blood
pressure). Among those 12 patients, the CVRwas classified as
high in 1 patient (8%), moderate in 8 (67%) patients, and low
in 3 (25%) patients.
3.3. Changes in Modifiable Cardiovascular Risk Factors at the
Three Time Points. Changes among the three time points of
the study in smoking habit, exercise, body mass index, use of
lipid-lowering drugs, and antihypertensive and oral antidia-
betic drugs/insulin were not routinely assessed or correctly
registered in the routine follow-up (were not coded). This
information was mainly available in the clinical record at
the time of the coronary event, but not in other points in
many patients. Similarly, in most cases, it was not possible to
evaluate variations in Framingham score, due to the lack of
necessary information to calculate it.
Metabolic parameters at the three time points are sum-
marized in Table 2.
Levels of LDL-cholesterol andHDL-cholesterol were only
determined in 18.5% of subjects at the baseline visit (previous
antiretroviral therapy); 46% of them had an LDL-cholesterol
level of >100mg/dL. At the time of the coronary event,
an LDL-cholesterol determination was available for 47% of
patients, and it was>100mg/dL in 45% of them. Finally, at the
last available visit (after the coronary event), LDL-cholesterol
determination was available for 73% of patients, and in 41% it
was >100mg/dL.
A significant decrease from the time of the coronary event
to the last visit available was observed in total cholesterol
[from 182 ((152, 230)mg/dL to 174 (147, 205), 𝑃 = 0.025] and
LDL-cholesterol [from 104 (98, 194)mg/dL to 95 (86, 124),
𝑃 = 0.004].
No significant differences among the three time points
were observed in HDL-cholesterol, total/HDL-cholesterol
ratio, triglyceride levels, and glycemia.
The percentage of patients receiving PIs with an unfavor-
able lipid profile decreased from 67% during the coronary
event to 37% at the last follow-up visit (𝑃 = 0.028), while
change to PIs with better lipid profile was from 33% to 63%
(𝑃 = 0.028) (Table 3).
The rate of patients with suppressedHIV-1 RNAviral load
significantly increased after the coronary event (𝑃 < 0.000).
4. Discussion
The prevalence of coronary events in our cohort of HIV-1-
infected subjects (2.15%) was lower than that observed by
other groups [29, 30]. The most frequent coronary events
were acute myocardial infarction and unstable angina, and
2.5% of them were fatal.
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Table 1: Patient characteristics at the time of the coronary event.
Characteristics HIV-infected patients (𝑛 = 81)
Age, years (median [IQR]) 48 (40, 57)
Patients > 50 years (%) 38.3
Gender (male) (%) 86.1
Body mass index >25 (%) 9.8
Men who have sex with men (%) 38.6
HCV coinfection (%) 4.9
HBV coinfection (%) 12.3
HIV-related characteristics
Time since diagnosis of HIV-infection, years (median [IQR]) 14.9 (10.4, 19.2)
Cumulative exposure to antiretrovirals (median [IQR]) 12.7 (9.3, 16.2)
Cumulative exposure to PIs (median [IQR]) 5 (0.7, 8)
Cumulative exposure to NNRTIs (median [IQR]) 3 (0.1, 7)
Cumulative exposure to abacavir (median [IQR]) 2 (0, 11)
CD4 cells count/𝜇L (median [IQR]) 224 (89, 422)
HIV-RNA ≤ 400 copies/mL (median [IQR]) 46 (56.8%)
Lipodystrophy (including lipoatrophy) (%) 36.1
Cardiovascular risk factors
Family history of coronary heart disease (%) 17 (20.5%)
Smoking (%) 36 (44%)
Cumulative exposure to tobacco smoke, years (mean [SD]) 23 (9.4)
Hypertension (%) 49 (60.5)
∗Use of antihypertensive treatment (%) 43 (87.8)
Diabetes mellitus (%) 13 (16)
∗Use of antidiabetic treatment (%) 10 (76.9)
Dyslipidemia (%) 44 (48.1)
Serum total cholesterol, mg/dL (median [IQR]) 182 (152, 230)
Serum HDL-cholesterol, mg/dL (median [IQR]) 42 (35, 52)
Serum LDL-cholesterol, mg/dL (median, [IQR]) 104 (98, 194)
Serum triglycerides, mg/dL (median, [IQR]) 168 (106, 248)
∗Use of lipid-lowering agents (%) 39 (88.6)
Data was reported as median and interquartile range [IQR].
∗Percentages of patients using antihypertensive drugs, antidiabetic treatment or lipid-lowering agents were calculated considering the number of patients
receiving that treatment with respect to those who required treatment (considering target parameters according to the guidelines).
Traditional CVRF were highly prevalent in patients with
a history of coronary heart disease at the time of the event.
The percentage of patients routinely undertaking fasting lipid
profiles significantly increased after the coronary event and
a decrease in total and LDL-cholesterol levels was observed
after the event. Nevertheless, many patients (41%) did not
achieve the recommended target in lipid parameters. Addi-
tionally, other CVRF such as smoking, lack of exercise, or
hypertension were not regularly controlled.
HIV-1-infected individuals receiving HAART have a
higher risk for ischemic heart disease than the general
population [1, 8–14, 17, 19, 24, 31, 32]. Previous studies report
incidence rates ranging from 1.53 to 6.01 cases per 1000
person-years in patients exposed to protease inhibitors [9]
and a progressive increase associated with the prolonged
exposure to antiretroviral therapy, particularly in patients on
a PI-containing regimen [8, 9, 12–14].
A meta-analysis including 19 studies evaluating cardio-
vascular and cerebrovascular events in Spanish population
showed that the prevalence of angina in Spain was about 7%,
while it was 2.6% in men and 3.5% in women aged from 25
to 74 years in another cohort [33–36]. In our HIV-1-infected
population, on the other hand, the prevalence of coronary
events was slightly lower (2.15%). Although the search was
exhaustive, it could be the possibility that not all cases were
recorded due to the retrospective design of the study.
The pathogenic mechanism of premature atheroscle-
rosis in HIV-1-infected individuals has not been clearly
defined, although it is considered a multifactorial process.
HIV infection and antiretroviral therapy might accelerate
atherogenesis, as do traditional risk factors. First, a chronic
systemic inflammatory state, endothelial dysfunction, and
prothrombotic state caused by the virus itself contribute to
the pathogenesis of coronary disease [4, 18–22]; therefore,
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Table 2: Changes in modifiable cardiovascular risk factors and Framingham score at the three time points of the study in the 81 included
patients.
Laboratory data Beforestarting ARV
At the time of
the coronary
eventa
Last observationb
c𝑃 value
(baseline to
coronary event)
d𝑃 value
(event to present)
CD4, cell/𝜇L (median [IQR]) 224 (89, 422) 497 (384, 776) 559 (375, 767) 0.000 0.201
HIV-RNA, log (median [IQR]) 4.6 (3.6, 5.3) 1.8 (1.4, 2.7) 1.4 (1.3, 1.7) 0.000 0.000
Serum total cholesterol, mg/dL (median [IQR]) 185 (154, 213) 182 (152, 230) 174 (147, 205) 0.402 0.025
Serum HDL-cholesterol, mg/dL (median [IQR]) 41 (30, 43) 42 (35, 52) 45 (33, 53) 0.155 0.974
Serum LDL-cholesterol, mg/dL (median [IQR]) 102 (97, 189) 104 (98, 194) 95 (86, 124) 0.305 0.004
CT/HDL-cholesterol ratio mmol/L 4.3 (3.8, 5.6) 4.1 (3.1, 5.8) 4 (3.1, 5.2) 0.110 0.339
Serum triglycerides, mg/dL (median [IQR]) 151 (106, 204) 168 (106, 248) 142 (95, 204) 0.778 0.111
Glycemia, mg/dL (median [IQR]) 90 (85, 103) 97 (88, 108) 95 (88, 108) 0.140 0.299
Glomerular filtration rate, mL/min (median [IQR]) 60 (60, 60) 60 (60, 60) 60 (60, 60) 0.317 0.317
Serum total cholesterol >200mg/dL (𝑛, %) 18 (49) 29 (45) 25 (35.2) 0.265 0.738
Serum HDL-cholesterol <40mg/dL (𝑛, %) 73 (90) 21 (44) 25 (39.7) 0.001 1.000
Serum LDL-cholesterol >100mg/dL (𝑛, %) 7 (46) 17 (45) 25 (41%) — 0.103
Serum triglycerides >200mg/dL (𝑛, %) 15 (41) 30 (37) 26 (32.1) 0.022 0.238
Serum triglycerides >500mg/dL (𝑛, %) 1 (2.7) 4 (6.3) 3 (4.1) 0.118 0.193
Glycemia >110mg/dL (𝑛, %) 5 (15) 15 (23) 17 (24.3) 0.001 0.52
Framingham <10% (low) (𝑛, %) 2 (50) 3 (25) 11 (44) — —
Framingham 10%–20% (moderate) (𝑛, %) 2 (50) 8 (67) 8 (32) — —
Framingham >20% (high) (𝑛, %) — 1 (8) 6 (24) — —
aMedian time (IQR) from starting antiretroviral treatment until the coronary event: 8 (5; 12) years; bmedian time (IQR) from the coronary event until the last
follow-up visit (June 2011): 7 (4; 11) years.
c
𝑃 value denotes change from baseline to the time of the coronary event; d𝑃 value denotes change from the coronary event to the last follow-up visit.
CT: total cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein.
Table 3: Current antiretroviral therapy during coronary event and at the last follow-up visit.
Coronary event
𝑛 (%)
Last follow-up visita
𝑛 (%) 𝑃 value
b
Without treatment (𝑛 = 28) 17 (20) 11 (14) 0.3
PI-based regimen (𝑛 = 68) 33 (41) 35 (43) 0.87
PI (with an unfavorable lipid profile) 22 (67) 13 (37) 0.028
Indinavir/r 7 (21) 2 (6) 0.13
Lopinavir/r 15 (45) 10 (29) 0.23
Fosamprenavir/r 0 1 (3) 1
PI (with a favorable lipid profile) 11 (33) 22 (63) 0.028
Saquinavir/r 2 (6) 0 0.45
Atazanavir/r 6 (18) 11 (31) 0.33
Darunavir/r 3 (9) 11 (31) 0.048
NNRTI-based regimen (𝑛 = 57) 26 (32) 31 (38) 0.51
Nevirapine 15 (58) 14 (45) 0.5
Efavirenz 11 (42) 17 (55) 0.5
Other treatments (𝑛 = 10) 6 (7) 4 (5) 0.74
Without treatment 0 5 (33) 1
Nucleoside reverse transcriptase inhibitor
Abacavir 15 (52) 14 (48) 1
aMedian time (IQR) from the coronary event until the last follow-up visit (June 2011): 7 (4; 11) years.
b
𝑃 values express intragroup differences between coronary event time and last visit (after event).
PI: protease inhibitors; NNRTI: nonnucleoside analog reverse-transcriptase inhibitors.
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viral suppression should be maintained to reduce vascular
damage [20, 37, 38]. The higher prevalence of coronary
atherosclerosis in young asymptomatic men with long-
standing HIV infection in comparison with non-HIV-1-
infected subjects supports the role of the virus [4, 18, 19,
32]. In our group of patients, viral suppression was present
in only half of them, at time of coronary event. Second,
although seemingly paradoxical, antiretroviral therapy could
also increase the risk of CVD [1, 8–14, 20], partly explained
by PI-related metabolic and lipid changes [9, 39, 40]. Both
HIV infection and antiretroviral therapy may contribute
independently to the increase of the cardiovascular risk and
acceleration of the pathogenesis of other conditions not
related to AIDS. Thus, physicians must be more proactive
with the management of HIV and interventions related to
switching treatments to drugs with better profile to limit the
potential cardiovascular damage.
Finally, traditional CVRF and smoking, cocaine use,
or coinfection with hepatitis C virus (all of which are
proatherogenic factors) are more common in HIV-1-infected
individuals than in the general population, [15–17, 34, 41].The
very high rates of smoking, hypertension, dyslipidemia, and
diabetes we observed in our group were consistent with those
of other cohorts of HIV-1-infected patients with myocardial
infarction [19, 31, 41, 42].
Fortunately, the incidence of cardiovascular events in the
HIV-1-infected population has fallen in recent years. This is
possibly as a result of more aggressive management of the
risk of CVD, the use of drugs with better cardiovascular
profile [25], and the viral suppression in almost all HIV-1-
infected patients in our setting that has limited the damage
of sustained viral replication in the vascular system. A
higher proportion of our patients showed viral suppression
in the last visit than at time of the coronary event. In
addition, the percentage of patients in our cohort receiving
antiretroviral drugswith a negative effect on lipidmetabolism
has decreased over time.
Surprisingly, in our cohort, the number of patients
who were receiving treatment for concomitant conditions
(lipid-lowering agents, antihypertensive drugs, or antidia-
betic drugs) was extremely high. Similarly, LDL- and HDL-
cholesterols were more frequently determined during recent
years, indicating increased efforts in achieving a better con-
trol of lipidmetabolism.However, treatment for dyslipidemia
was suboptimal or poorly controlled in most cases. Lipid
levels improved after the coronary event, although almost
half (41%) of the patients maintained an LDL-cholesterol
level > 100mg/dL after the coronary event. Second, other
CVRF, such as smoking, hypertension, lack of exercise, and
body mass index, are not routinely assessed. These data
were not available in the clinical histories of most of our
patients, suggesting poor monitoring of these risk factors in
our clinical practice.
The mortality rate registered in our cohort among
subjects with previous coronary events was 2.5%, slightly
lower than that observed by other groups (4.2%) [30].
Although our search was exhaustive, we cannot rule out
(given the retrospective study design) the possibility that
some cardiovascular-related deaths were not included in our
database or were attributed to “unknown causes” and have
not been captured in the analysis.
The retrospective design of our study did not enable us to
determine the real rate of some risk factors and thus evaluate
changes. However, the study provides us a clear picture of
real clinical practice. In addition, despite performing an
exhaustive search, we cannot exclude the possibility ofmissed
coronary events attended at other centers and not reported in
our database. However, this rate would be low and is unlikely
to drive a significant change in the study results.
In summary, the management of CVRF in our cohort
was far from optimal, in subjects already diagnosed for prior
CV major events. However, as this group is aging, we expect
a progressive increase in the incidence of CVD paralleling
the age group. Cardiovascular health plans are a priority if
this increase is to be curbed and need to carefully monitor
the CVRF to assess the effectiveness of such plans. Optimal
selection of antiretroviral treatment, together with aggressive
management of other modifiable risk factors, will diminish
cardiovascular risk in HIV-1-infected patients.
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